Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH2 | P48735 | 8/20 | 0.39 |
| ▸ | KDM1A | O60341 | 7/20 | 0.38 |
| ▸ | MAOB | P27338 | 6/20 | 0.38 |
| ▸ | MAOA | P21397 | 4/20 | 0.36 |
| ▸ | RPS6KB1 | P23443 | 4/20 | 0.36 |
| ▸ | AKT1 | P31749 | 2/20 | 0.36 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.36 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.36 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.36 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.36 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.36 |
| ▸ | RPS6KB2 | Q9UBS0 | 1/20 | 0.36 |
| ▸ | RPS6KA6 | Q9UK32 | 1/20 | 0.36 |
| ▸ | KIT | P10721 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19706122 | 0.92 | IDH2 (0.46) | IDH2KDM1A | |
| SCHEMBL20633241 | 0.87 | RHOA (0.41) | IDH2RPS6KB1AKT1 | |
| SCHEMBL17618786 | 0.83 | FYN (0.42) | IDH2KDM1AMAOBMAOAKIT | |
| SCHEMBL20632424 | 0.76 | KDM1A (0.46) | IDH2KDM1ARPS6KB1AKT1 | |
| SCHEMBL17618783 | 0.75 | MEN1 (0.47) | IDH2KIT | |
| SCHEMBL17618348 | 0.75 | IDH2 (0.45) | IDH2 | |
| SCHEMBL17618796 | 0.74 | MEN1 (0.45) | IDH2 | |
| SCHEMBL17618816 | 0.74 | CYP1A2 (0.48) | IDH2 | |
| SCHEMBL17618354 | 0.73 | HTR2C (0.48) | IDH2KIT | |
| SCHEMBL17618820 | 0.73 | MEN1 (0.43) | IDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2020-03-17 | — | — | US | disclosed |
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | IDH2 34/4885KDM1A 859/4885MAOB 985/4885 |
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | SIRT1, SIRT3, SIRT2 | IDH2 34/4885KDM1A 859/4885MAOB 985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.